Polymerase News and Research

RSS

Novel multi-analyte approach to develop urine-biomarker based diagnostic assay to be presented

Predictive Biosciences today announced that Company scientists will be presenting a novel multi-analyte approach to the development of a non-invasive, urine-biomarker based diagnostic assay during the 10th Annual Meeting of the Society of Urologic Oncology (SUO).

3 Dec 2009

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProParaflu+(TM) assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections.

25 Nov 2009

Enrollment for ongoing phase 2b trial of RG7128 announced

Pharmasset, Inc. announced today that the enrollment of Cohort 2, led by its partner Roche, will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

23 Nov 2009

BD acquires HandyLab for $275 million

BD today announced the completion of its acquisition of HandyLab, Inc., an Ann Arbor, Michigan-based company that develops and manufactures molecular diagnostic assays and automation platforms.

From BD (Becton, Dickinson and Company) 20 Nov 2009

DxNA announces successfull evaluation of its GeneSTAT PCR system

DxNA, a molecular diagnostics company headquartered in St. George, Utah, announced today that the DxNA GeneSTAT PCR system has successfully completed evaluation studies under the direction of a California laboratory supported by the Joint FAO/IAEA Programme in Food and Agriculture.

19 Nov 2009

Quest Diagnostics' Simplexa Influenza A H1N1 (2009) test receives CE mark

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test kit for distribution to approximately 35 countries in Europe.

From Quest Diagnostics 18 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Agilent Technologies acquires MassCode Tag technology from Eurofins MWG Operon

Agilent Technologies Inc. today announced it has purchased the MassCode Tag technology from Eurofins MWG Operon, a division of Eurofins. The purchase includes the MassCode trademarks and intellectual property, including four families of patents.

17 Nov 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment.

9 Nov 2009

Third-quarter 2009 financial results announced by Inhibitex

Inhibitex, Inc., today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.

6 Nov 2009

New therapeutic approach targets cancer cells, not normal cells

The ultimate goal in cancer research, a treatment that kills cancer cells whilst leaving healthy cells untouched, is brought nearer by the success of a new therapeutic approach. The potential therapy, published in BioMed Central's open access journal Breast Cancer Research, targets proliferation of cancer, but not normal, cells.

5 Nov 2009

Report on the global anti-infectives market

MarketResearch.com has announced the addition of Kalorama Information's new report "The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)," to their collection of Healthcare market reports.

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Gen-Probe receives FDA emergency use authorization for its Prodesse ProFlu-ST test

Gen-Probe Incorporated today announced that the US Food and Drug Administration (FDA) has granted an EUA (emergency use authorization) for its test, the Prodesse ProFlu-ST(TM), to be used in CLIA high complexity laboratories for the diagnosis of 2009 H1N1 influenza virus infection, aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices.

29 Oct 2009

Supportive data from a preclinical study of SCY-635 to be presented

Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009.

29 Oct 2009

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Scientists here have identified how the motions of an enzyme are related to correctly copying genetic instructions, setting the stage for studies that can uncover what happens when DNA copying mistakes are made.

28 Oct 2009

ISO 9001:2008 certification for Kapa Biosystems

Life science reagents supplier Kapa Biosystems announced today that its Research, Development and Manufacturing facility has received ISO 9001:2008 certification from SABS Commercial (Pty) Ltd.

27 Oct 2009

Emodin raises hope for treatment of fibrotic liver diseases

In the last decade, advances in the understanding of genes promoting hepatic stellate cell (HSC) activation are impressive. However, there are few breakthroughs in therapeutic intervention of hepatic fibrogenesis. Efficient and well-tolerated antifibrotic drugs are lacking and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Research identifying innocuous antifibrotic agents is of high priority and urgently needed.

24 Oct 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009